{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:56:55Z","timestamp":1789844215932,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejim.2025.106627","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T04:36:23Z","timestamp":1765946183000},"page":"106627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-3178","authenticated-orcid":false,"given":"Elisa","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Venturelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Leoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Viazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1238-872X","authenticated-orcid":false,"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.106627_bib0001","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.106627_bib0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106627_bib0003","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2025.106627_bib0004","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal Syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106627_bib0005","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/ndt\/gfq066","article-title":"Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference","volume":"25","author":"Bagshaw","year":"2010","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2025.106627_bib0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106627_bib0007","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.120.15205","article-title":"Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure","volume":"76","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.106627_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10741-011-9262-2","article-title":"New roles for renin and prorenin in heart failure and cardiorenal crosstalk","volume":"17","author":"Schroten","year":"2012","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2025.106627_bib0009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00392-008-0732-z","article-title":"Differential associations between renal function and \u2018modifiable\u2019 risk factors in patients with chronic heart failure","volume":"98","author":"Smilde","year":"2009","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2025.106627_bib0010","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of Sacubitril-Valsartan vs Enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2025.106627_bib0011","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106627_bib0012","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106627_bib0013","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2025.106627_bib0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.106627_bib0016","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014The Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.106627_bib0017","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0018","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.109.853648","article-title":"Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure","volume":"120","author":"Anand","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106627_bib0019","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.106627_bib0020","first-page":"214","article-title":"Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure","volume":"3","author":"Kiernan","year":"2015","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.ejim.2025.106627_bib0021","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin inhibition versus Enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0022","first-page":"489","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.ejim.2025.106627_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029565","article-title":"Updates for cardio-kidney protective effects by angiotensin receptor-neprilysin inhibitor: requirement for additional evidence of kidney protection","volume":"12","author":"Tsukamoto","year":"2023","journal-title":"JAHA"},{"key":"10.1016\/j.ejim.2025.106627_bib0024","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijchv.2014.03.005","article-title":"Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives","volume":"3","author":"Vizzardi","year":"2014","journal-title":"IJC Heart Vessels"},{"key":"10.1016\/j.ejim.2025.106627_bib0026","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0028","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.106627_bib0029","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.106627_bib0030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106627_bib0031","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0032","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","author":"Mc Causland","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.106627_bib0033","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0034","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106627_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 Inhibitors and their mode of action in heart failure-has the mystery been unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ejim.2025.106627_bib0037","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ejim.2025.106627_bib0038","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0039","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of Dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106627_bib0041","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106627_bib0042","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of Empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106627_bib0043","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0044","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.106627_bib0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2025.106627_bib0046","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.106627_bib0047","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tcm.2025.05.002","article-title":"The role of finerenone in heart failure","volume":"35","author":"Ismahel","year":"2025","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2025.106627_bib0048","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.106627_bib0049","doi-asserted-by":"crossref","first-page":"sfae169","DOI":"10.1093\/ckj\/sfae169","article-title":"Assessment of SGLT2 inhibitors\u2019 safety and discontinuation causes in patients with advanced chronic kidney disease: insights from a real-world data analysis","volume":"17","author":"Perrin","year":"2024","journal-title":"Clin Kidney J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525005047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525005047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:16:30Z","timestamp":1776021390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525005047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S0953620525005047"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106627","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106627"}}